Urinary IncontinenceIncontiLibNCT05938855
Performance and Safety of the PHENIX LIBERTY, a Medical Device for Electrostimulation and Biofeedback, in the Treatment of Pelvic Static Disorders in Women With Urinary Incontinence.
A study testing Electrical stimulation and biofeedback with the medical device Phenix Liberty in people with Urinary Incontinence and Pelvic Floor Disorders, run by Vivaltis at 2 sites in France.
Trial summary
The goal of this clinical trial is to evaluate the short-term improvement in urinary incontinence after perineo-sphincter rehabilitation using functional electrostimulation and biofeedback (PHENIX LIBERTY VIVALTIS device) in patients with pelvic statics disorders. Read more about this study
- Who is it for?
- Ages 18 to 75 years, women only
- Conditions the study is for
- Urinary Incontinence, Pelvic Floor Disorders
- What is being tested?
- Electrical stimulation and biofeedback with the medical device Phenix Liberty
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 30 participants
- Where
- 2 sitesFrance
- Study dates
- 6 May 2024to 6 Dec 2024
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- Women only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patient who is incontinent (involuntary loss of urine) and/or has an overactive bladder (pollakiuria defined as more than one nocturnal urination and more than six daytime urination or leakage per day); Incontinent patient requiring functional rehabilitation of pelvic static disorders by electrostimulation and biofeedback;
- Adult patient (between 18 / 75 years old);
- Patient with at least one of the following symptoms related to a pelvic static disorder: pain, hypertonia, muscle weakness, decreased or loss of motor control, trophic abnormality;
- Patient who can make herself available to participate in the sessions regularly and who believes that she will be able to complete the tenth treatment session no later than 8 weeks after V0;
- Patient who has signed the consent form to participate in the study;
- Patient physically and mentally willing and able, in the judgment of the investigator at the time of recruitment, to perform the procedures under study;
- Patient with social protection.
Who cannot join
- Patient with peripheral or central neurological involvement (perianal or perivulvar sensitivity disorder);
- Patient with BMI ≥30 kg/m²
- Patient who has had more than 3 deliveries;
- Patient with stroke, Alzheimer's, multiple sclerosis, spinal cord involvement, narrow lumbar canal, cauda equina syndrome, or cognitive and/or behavioral impairment that may, in the practitioner's judgment, interact with the self-questionnaire or biofeedback assessment;
- Pregnant woman at the inclusion visit;
- Patient with an implanted pacemaker or spinal cord trainer;
Show all 14Show fewer
- Patient with hypersensitivity to electrostimulation;
- Patient with such vaginal atrophy that an endovaginal probe cannot be used
- Patient with chronic or recurrent vaginal or urinary tract infection on long-term treatment;
- Patient with vaginal pathology (undiagnosed bleeding, cancer in the area to be treated);
- Patient who has renounced her liberty by administrative or judicial sentence, or who is under guardianship or limited judicial protection;
- Patient participating in an interventional clinical trial or testing/having tested an investigational drug and/or medical device within 30 days prior to inclusion in the study in relation to the relevant pathology;
- Patient who cannot read or write French;
- Patient refusing to participate in the study.
Trial locations and contacts
2 sites in 1 country.
France2 sites
Pôle santé de la Nartassière
Mouans-Sartoux, 06370
Human Physio
Nîmes, 30000
About this study
Official title: Prospective Evaluation of the Performance and Safety of PHENIX LIBERTY, a Medical Device for Electrostimulation and Biofeedback, in the Treatment of Pelvic Static Disorders in Women With Urinary Incontinence.
The goal of this clinical trial is to evaluate the short-term improvement in urinary incontinence after perineo-sphincter rehabilitation using functional electrostimulation and biofeedback (PHENIX LIBERTY VIVALTIS device) in patients with pelvic statics disorders.
- Does the use of the medical device in the treatment of pelvic static disorders lead to an improvement in urinary incontinence?
Participants will use the medical device, which provides electrical stimulation, biofeedback and pressure biofeedback to re-educate the pelvic floor muscles and improve urinary incontinence.
Read the detailed description
Rational :
Urinary incontinence is a condition affecting many women in their adult lives. It is considered a public health problem, and has a high negative impact on patients' quality of life. Physiotherapy-based perineal rehabilitation is considered the first-line treatment for this condition. Treatments consist of pelvic floor muscle exercises (physiotherapy) with or without the use of other resources such as biofeedback, electrical electro-stimulation and vaginal cones.
In this context, the promoter wishes to carry out this study in order to reinforce the data currently available on the medical device PHENIX LIBERTY.
Design:
Prospective, interventional with non invasive and non burdensome procedure, non-comparative, multicenter, open-label study of a CE-marked medical device.
Intervention :
As part of this clinical investigation, the medical device under investigation is used in accordance with its usual use, and the patient's therapeutic procedure includes additional, non-invasive procedures. These additional procedures relate to the addition of an end-of-life visit and validated questionnaires assessing functional deficiencies and impact on daily life.
The care will be conduct as follow:
- 1 inclusion visit (V0) (from 1 say to 15 days prior the the first functional therapeutic re-education session)
- 10 sessions of functional therapeutic re-education, during which the PHENIX LIBERTY device may be used. Sessions performed at regular intervals according to a schedule drawn up by the physiotherapist (between 10 and 12 weeks)
- 1 end visit (V11), 1 week after the 10th session to complet questionnaires
In total, the patient will be followed 15 weeks maximum
- Conditions
- Urinary Incontinence, Pelvic Floor Disorders
- Being tested
- Electrical stimulation and biofeedback with the medical device Phenix Liberty
- Keywords
- Electrical stimulation, Biofeedback
- Medical subject headings
- Urinary Incontinence, Pelvic Floor Disorders
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Electrical stimulation and biofeedback with the medical device Phenix LibertyDevice
The patient will undergo 10 therapeutic functional re-education sessions, at regular intervals according to a schedule drawn up by the physiotherapist, during which the PHENIX LIBERTY device may be used.
The patients will complete questionnaires at the end of the care Overall, the functional perineal rehabilitation sessions will include muscle testing, electrostimulation and biofeedback.
The follow up will be conduct as follow :
- 10 sessions between 10 and 12 weeks
- 1 end visit, within the week after the 10th session
| Study group | Role | What they receive |
|---|---|---|
| Standard of care plus additional questionaire | Other | As part of this clinical investigation, the medical device under investigation is used in accordance with its usual use, and the patient's therapeutic procedure includes additional, non-invasive procedures. These additional procedures relate to the addition of an end-of-life visit and validated questionnaires assessing functional deficiencies and impact on daily life. Receives: Device: Electrical stimulation and biofeedback with the medical device Phenix Liberty |
What is being measured
The primary outcome is the main question the study is designed to answer.
Changes in the frequency of bladder weakness
A mictional grid will be used
The mictional grid covers a period of forty-eight to seventy-two hours. It assesses the number of micturitions during the day and at night, and quantifies the volume of urine passed at each micturition, as well as diuresis over a 24-hour period. The mictional grid visualizes episodes of leakage, their quantity (small drops, beginning of micturition or massive leakage) and the moment of onset, such as during effort (coughing, sneezing, carrying a load, sport, etc.) or at rest.
Measured: Day 0 and Week 15 (at the end visit within the week after the 10th seance)
Secondary outcomes (18)
Changes in the Pelvic Floor Impact Questionnaire (PFIQ-7) score assessing the impact of pelvic static disorders
The Pelvic Floor Impact Questionnaire (PFIQ-7) will be used, it assess the social impact of pelvic statics disorders.
The questionnaire has 7 questions and 3 columns. The first column concerns urinary symptoms, the 2nd column concerns colorectal-anal symptoms and the 3rd column concerns genital prolapse symptoms.
All questions use the following answer format:
- Not at all = 0
- Somewhat = 1
- Moderately = 2
- A lot = 3
Each column gives a score between 0 and 100, which will be added to give the total score of the PFIQ-7 scale between 0 and 300.
A high score indicates a significant impact of pelvic static disorders
Measured: Day 0 and Week 15 (at the end visit within the week after the 10th seance)
Change in patients' visual analog scale (VAS) pain scores
The pain caused by the pelvic floor disorder will be assessed by the Visual Analogue Scale (VAS).
The VAS is made up of a 10-centimeter line anchored by two ends of the pain. 10 is the first end being the "maximum pain imaginable" and 0 is the other end being "no pain".
Measured: Day 0 and Week 15 (at the end visit within the week after the 10th seance)
Changes in the number of voids during the day and at night,
The number of voids during the day and at night will be assessed.
The same mictional grid will be used
The mictional grid covers a period of forty-eight to seventy-two hours. It assesses the number of micturitions during the day and at night, and quantifies the volume of urine passed at each micturition, as well as diuresis over a 24-hour period. The mictional grid visualizes episodes of leakage, their quantity (small drops, beginning of micturition or massive leakage) and the moment of onset, such as during effort (coughing, sneezing, carrying a load, sport, etc.) or at rest.
Measured: Day 0 and Week 15 (at the end visit within the week after the 10th seance)
Change in the severity of leakage
The severity of leakage will be assessed (small drops, onset of micturition or massive leakage)
The same mictional grid will be used
The mictional grid covers a period of forty-eight to seventy-two hours. It assesses the number of micturitions during the day and at night, and quantifies the volume of urine passed at each micturition, as well as diuresis over a 24-hour period. The mictional grid visualizes episodes of leakage, their quantity (small drops, beginning of micturition or massive leakage) and the moment of onset, such as during effort (coughing, sneezing, carrying a load, sport, etc.) or at rest.
Measured: Day 0 and Week 15 (at the end visit within the week after the 10th seance)
Change in diuresis over twenty-four hours;
The number of voiding sensation over twenty-four hours will be assessed
The same mictional grid will be used
The mictional grid covers a period of forty-eight to seventy-two hours. It assesses the number of micturitions during the day and at night, and quantifies the volume of urine passed at each micturition, as well as diuresis over a 24-hour period. The mictional grid visualizes episodes of leakage, their quantity (small drops, beginning of micturition or massive leakage) and the moment of onset, such as during effort (coughing, sneezing, carrying a load, sport, etc.) or at rest.
Measured: Day 0 and Week 15 (at the end visit within the week after the 10th seance)
Change in the volume of urine voided at each voiding
The volume of urine voided at each voiding will be assessed in deciliter
The same mictional grid will be used
The mictional grid covers a period of forty-eight to seventy-two hours. It assesses the number of micturitions during the day and at night, and quantifies the volume of urine passed at each micturition, as well as diuresis over a 24-hour period. The mictional grid visualizes episodes of leakage, their quantity (small drops, beginning of micturition or massive leakage) and the moment of onset, such as during effort (coughing, sneezing, carrying a load, sport, etc.) or at rest.
Measured: Day 0 and Week 15 (at the end visit within the week after the 10th seance)
Changes in the rate of improvement in perineal protection reflex during a coughing effort
A surface Electromyography (EMG) will be used. Muscle electrical activity provides a "map" of muscle recruitment according to exercise conditions (position, relative load, type of resistance, type of support, etc.).
Measured: Day 0 and Week 15 (at the end visit within the week after the 10th seance)
Changes in the rate of improvement of hypertonia assessed through measurement of myoelectric activity
A surface Electromyography (EMG) will be used. Muscle electrical activity provides a "map" of muscle recruitment according to exercise conditions (position, relative load, type of resistance, type of support, etc.).
Measured: Day 0 and Week 15 (at the end visit within the week after the 10th seance)
Changes in the rate of improvement in hypertonia assessed through measurement of perineal muscle tone
Modified Oxford gradient will be used. This is an assessment of pelvic floor muscle strength by the practitioner, using vaginal palpation.
The score is scored as follows: 0 → no detectable pelvic floor contraction , 1 → very weak pelvic floor contraction, 2 → weak pelvic floor contraction, 3 → moderate pelvic floor contraction, 4 → good pelvic floor contraction, 5 → strong pelvic floor contraction
Measured: Day 0 and Week 15 (at the end visit within the week after the 10th seance)
Evolution of vaginal microcirculation and trophicity according to the practitioner's subjective opinion
This outcome will be assessed according to the practitioner's opinion regarding visual assessment, palpation assessment of the vagina.
The practitioners will indicated if on his opinion there is a an abnormal vaginal microcirculation and trophicity.
Measured: Day 0 and Week 15 (at the end visit within the week after the 10th seance)
Changes in the rate of improvement in awakening and muscle strengthening assessed through measurement of myoelectric activity
A surface Electromyography (EMG) and a vaginal intra-cavity probe will be used. Muscle electrical activity provides a "map" of muscle recruitment according to exercise conditions (position, relative load, type of resistance, type of support, etc.).
Measured: Day 0 and Week 15 (at the end visit within the week after the 10th seance)
Changes in the rate of improvement in awakening and muscle strengthening assessed through measurement of perineal muscle tone
Modified Oxford gradient will be used. This is an assessment of pelvic floor muscle strength by the practitioner, using vaginal palpation.
The score is scored as follows: 0 → no detectable pelvic floor contraction , 1 → very weak pelvic floor contraction, 2 → weak pelvic floor contraction, 3 → moderate pelvic floor contraction, 4 → good pelvic floor contraction, 5 → strong pelvic floor contraction
Measured: Day 0 and Week 15 (at the end visit within the week after the 10th seance)
Percentage of patients with an improvement in pelvic statics
This outcome will be assessed according to the practitioner's opinion
Measured: Day 0 and Week 15 (at the end visit within the week after the 10th seance)
Incidence of adverse events
Rate of the incidence of adverse events related to the medical device
Measured: At each visit, from day 0 to Week 15 (at the end visit within the week after the 10th seance)
Evaluation of the Global Impression of Change Scale score after therapeutic management
The Patient's Global Impression of Change (PGIC) Scale is a questionnaire designed to express the patient's overall impression of changes in symptoms, activities, emotions and quality of life following therapeutic treatment17. The patient answers the first question by ticking one of the proposed answers, each answer corresponding to a score from 1 to 7. The patient then scores his or her impression of progress on a scale from 0 to 10.
Measured: Week 15 (at the end visit within the week after the 10th seance)
Evaluation of responses to the patient satisfaction questionnaire on the use of the PHENIX LIBERTY device after therapeutic management
The satisfaction questionnaire is constructed on the basis of the Likert Scale. The sponsor has written an questionnaire regarding the use of the Phenix Liberty for the patient.
The Likert scale (or attitude scale) is a semantic rating system, generally consisting of 5 or 7 items, used in surveys to measure and evaluate perceptions, attitudes and opinions.
The evaluation will be based on the following responses: Strongly agree (=5) ; Agree (=4) ; Rather agree (=3) ; Rather disagree (=2) ; Disagree (=1= ; Strongly disagree (=0).
The minimum score 0 means a worse outcome and the maximum score 5 means a better outcome.
Measured: Week 15 (at the end visit within the week after the 10th seance)
Evolution of the vaginal lubrication and hydration score for the evaluation of microcirculation and vaginal trophicity
Vaginal lubrication and hydration can also be used to assess vaginal microcirculation and trophicity. This parameter is observed by the practitioner through visual and tactile observation. The score is as follows: 1 → no vaginal lubrication/hydration (altered mucosa), 2 → no vaginal lubrication/hydration (unaltered mucosa), 3 → very low vaginal lubrication/hydration, 4 → moderate vaginal lubrication/hydration, 5 → normal vaginal lubrication/hydration.
Measured: Day 0 and Week 15 (at the end visit within the week after the 10th seance)
Evolution of the vaginal acidity score for assessing vaginal microcirculation and trophicity
Vaginal pH is an important element in determining vaginal health, encompassing microcirculation and vaginal trophicity. The vagina is an acidic environment (pH ≤ 4.6) thanks to its healthy bacterial flora, which secrete lactic acid to limit the growth of many pathogenic microbes. A scale will be used to frame the different pH values. The score is as follows: 1 → pH ≥6.1, 2 → pH = 5.6-6, 3 → 5.1-5.5, 4 → 4.7-5.0, 5 → ≤4.6. (Appendix 6bis) Score 1 represents an abnormal pH and score 5 represents a normal pH.
Measured: Day 0 and Week 15 (at the end visit within the week after the 10th seance)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Jul 2023
- Study start6 May 2024
- Primary completion6 Dec 2024
- Study completion6 Dec 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Urinary IncontinenceStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 30 participants (actual)
Sponsor and investigators
- Lead sponsor
- Vivaltis
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- CEISO, Human Physio, Pôle santé de la Nartassière
- Responsible party
- Sponsor
- Investigators
- Mathias Willame, Principal investigator, Human PhysioJulie Perrin, Principal investigator, Pôle santé de la Nartassière
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05938855
- Sponsor's protocol ID
- 2023-A02195-40
- Acronym
- IncontiLib
- Status last verified
- Dec 2024
- First submitted
- 22 Jun 2023
- Last updated
- 16 Dec 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 16 Dec 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Prospective Evaluation of the Performance and Safety of PHENIX LIBERTY, a Medical Device for Electrostimulation and Biofeedback, in the Treatment of Pelvic Static Disorders in Women With Urinary Incontinence.
- ClinicalTrials.gov ID
- NCT05938855
- Acronym / sponsor ID
- IncontiLib / 2023-A02195-40
- Conditions
- Urinary Incontinence, Pelvic Floor Disorders
- Keywords
- Electrical stimulation, Biofeedback
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 30 participants (actual)
- Lead sponsor
- VivaltisIndustry (pharma, biotech, devices)
- Collaborators
- CEISO, Human Physio, Pôle santé de la Nartassière
- Study start
- 6 May 2024 (actual)
- Primary completion
- 6 Dec 2024 (actual)
- Study completion
- 6 Dec 2024 (actual)
- First posted
- 11 Jul 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to evaluate the short-term improvement in urinary incontinence after perineo-sphincter rehabilitation using functional electrostimulation and biofeedback (PHENIX LIBERTY VIVALTIS device) in patients with pelvic statics disorders.
- Does the use of the medical device in the treatment of pelvic static disorders lead to an improvement in urinary incontinence?
Participants will use the medical device, which provides electrical stimulation, biofeedback and pressure biofeedback to re-educate the pelvic floor muscles and improve urinary incontinence.
Detailed description
Rational :
Urinary incontinence is a condition affecting many women in their adult lives. It is considered a public health problem, and has a high negative impact on patients' quality of life. Physiotherapy-based perineal rehabilitation is considered the first-line treatment for this condition. Treatments consist of pelvic floor muscle exercises (physiotherapy) with or without the use of other resources such as biofeedback, electrical electro-stimulation and vaginal cones.
In this context, the promoter wishes to carry out this study in order to reinforce the data currently available on the medical device PHENIX LIBERTY.
Design:
Prospective, interventional with non invasive and non burdensome procedure, non-comparative, multicenter, open-label study of a CE-marked medical device.
Intervention :
As part of this clinical investigation, the medical device under investigation is used in accordance with its usual use, and the patient's therapeutic procedure includes additional, non-invasive procedures. These additional procedures relate to the addition of an end-of-life visit and validated questionnaires assessing functional deficiencies and impact on daily life.
The care will be conduct as follow:
- 1 inclusion visit (V0) (from 1 say to 15 days prior the the first functional therapeutic re-education session)
- 10 sessions of functional therapeutic re-education, during which the PHENIX LIBERTY device may be used. Sessions performed at regular intervals according to a schedule drawn up by the physiotherapist (between 10 and 12 weeks)
- 1 end visit (V11), 1 week after the 10th session to complet questionnaires
In total, the patient will be followed 15 weeks maximum
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Standard of care plus additional questionaire | Other | Device: Electrical stimulation and biofeedback with the medical device Phenix LibertyAs part of this clinical investigation, the medical device under investigation is used in accordance with its usual use, and the patient's therapeutic procedure includes additional, non-invasive procedures. These additional procedures relate to the addition of an end-of-life visit and validated questionnaires assessing functional deficiencies and impact on daily life. |
Who may qualify
- Ages
- 18 to 75 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- Patient who is incontinent (involuntary loss of urine) and/or has an overactive bladder (pollakiuria defined as more than one nocturnal urination and more than six daytime urination or leakage per day); Incontinent patient requiring functional rehabilitation of pelvic static disorders by electrostimulation and biofeedback;
- Adult patient (between 18 / 75 years old);
- Patient with at least one of the following symptoms related to a pelvic static disorder: pain, hypertonia, muscle weakness, decreased or loss of motor control, trophic abnormality;
- Patient who can make herself available to participate in the sessions regularly and who believes that she will be able to complete the tenth treatment session no later than 8 weeks after V0;
- Patient who has signed the consent form to participate in the study;
Key exclusion criteria (14 listed)
- Patient with peripheral or central neurological involvement (perianal or perivulvar sensitivity disorder);
- Patient with BMI ≥30 kg/m²
- Patient who has had more than 3 deliveries;
- Patient with stroke, Alzheimer's, multiple sclerosis, spinal cord involvement, narrow lumbar canal, cauda equina syndrome, or cognitive and/or behavioral impairment that may, in the practitioner's judgment, interact with the self-questionnaire or biofeedback assessment;
- Pregnant woman at the inclusion visit;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Electrical stimulation and biofeedback with the medical device Phenix LibertyThe patient will undergo 10 therapeutic functional re-education sessions, at regular intervals according to a schedule drawn up by the physiotherapist, during which the PHENIX LIBERTY device may be used. The patients will complete questionnaires at the end of the care Overall, the functional perineal rehabilitation sessions will include muscle testing, electrostimulation and biofeedback. The follow up will be conduct as follow : * 10 sessions between 10 and 12 weeks * 1 end visit, within the week after the 10th session | Device | Standard of care plus additional questionaire |
Primary outcome
Changes in the frequency of bladder weakness
Time frame: Day 0 and Week 15 (at the end visit within the week after the 10th seance)
A mictional grid will be used The mictional grid covers a period of forty-eight to seventy-two hours. It assesses the number of micturitions during the day and at night, and quantifies the volume of urine passed at each micturition, as well as diuresis over a 24-hour period. The mictional grid visualizes episodes of leakage, their quantity (small drops, beginning of micturition or massive leakage) and the moment of onset, such as during effort (coughing, sneezing, carrying a load, sport, etc.) or at rest.
18 secondary outcomes
Changes in the Pelvic Floor Impact Questionnaire (PFIQ-7) score assessing the impact of pelvic static disorders
Time frame: Day 0 and Week 15 (at the end visit within the week after the 10th seance)
Change in patients' visual analog scale (VAS) pain scores
Time frame: Day 0 and Week 15 (at the end visit within the week after the 10th seance)
Changes in the number of voids during the day and at night,
Time frame: Day 0 and Week 15 (at the end visit within the week after the 10th seance)
Change in the severity of leakage
Time frame: Day 0 and Week 15 (at the end visit within the week after the 10th seance)
Change in diuresis over twenty-four hours;
Time frame: Day 0 and Week 15 (at the end visit within the week after the 10th seance)
Change in the volume of urine voided at each voiding
Time frame: Day 0 and Week 15 (at the end visit within the week after the 10th seance)
Changes in the rate of improvement in perineal protection reflex during a coughing effort
Time frame: Day 0 and Week 15 (at the end visit within the week after the 10th seance)
Changes in the rate of improvement of hypertonia assessed through measurement of myoelectric activity
Time frame: Day 0 and Week 15 (at the end visit within the week after the 10th seance)
Changes in the rate of improvement in hypertonia assessed through measurement of perineal muscle tone
Time frame: Day 0 and Week 15 (at the end visit within the week after the 10th seance)
Evolution of vaginal microcirculation and trophicity according to the practitioner's subjective opinion
Time frame: Day 0 and Week 15 (at the end visit within the week after the 10th seance)
Changes in the rate of improvement in awakening and muscle strengthening assessed through measurement of myoelectric activity
Time frame: Day 0 and Week 15 (at the end visit within the week after the 10th seance)
Changes in the rate of improvement in awakening and muscle strengthening assessed through measurement of perineal muscle tone
Time frame: Day 0 and Week 15 (at the end visit within the week after the 10th seance)
Percentage of patients with an improvement in pelvic statics
Time frame: Day 0 and Week 15 (at the end visit within the week after the 10th seance)
Incidence of adverse events
Time frame: At each visit, from day 0 to Week 15 (at the end visit within the week after the 10th seance)
Evaluation of the Global Impression of Change Scale score after therapeutic management
Time frame: Week 15 (at the end visit within the week after the 10th seance)
Evaluation of responses to the patient satisfaction questionnaire on the use of the PHENIX LIBERTY device after therapeutic management
Time frame: Week 15 (at the end visit within the week after the 10th seance)
Evolution of the vaginal lubrication and hydration score for the evaluation of microcirculation and vaginal trophicity
Time frame: Day 0 and Week 15 (at the end visit within the week after the 10th seance)
Evolution of the vaginal acidity score for assessing vaginal microcirculation and trophicity
Time frame: Day 0 and Week 15 (at the end visit within the week after the 10th seance)
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Dec 2024.
Related trials for Urinary Incontinence
Recruiting
Safety and Performance of UCon Patch Electrode
Urinary Incontinence, Urinary Incontinence, Urge
Active, not recruitingPhase 2/3
Examining the Effects of Intra-detrusor Botox at Time of HoLEP in Men With Overactive Bladder Symptoms
Urinary Incontinence, Overactive Bladder Syndrome
Recruiting
Rehabilitation and Sex Therapy to Optimize Recovery After Prostate Cancer Treatment
Prostate Cancer, Urinary Incontinence
Recruiting
UCon Treatment of Overactive Bladder (OAB) in Males
Urinary Incontinence, Urge Incontinence
Active, not recruitingObservational study
Overactive Bladder Symptoms and Urinary Incontinence In Women With Rheumatoid Arthritis
Rheumatoid Arthritis, Rheumatoid Arthritis (RA)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Mathias Willame principal investigator
Human Physio
Julie Perrin principal investigator
Pôle santé de la Nartassière
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Electrical stimulation and biofeedback with the medical device Phenix Liberty in people with Urinary Incontinence and Pelvic Floor Disorders, run by Vivaltis at 2 sites in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 14 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 16 Dec 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Changes in the frequency of bladder weakness (time frame: Day 0 and Week 15 (at the end visit within the week after the 10th seance)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Dec 2024.